NNC 0172-0000-2021
NN7415-3813
Phase 1 small_molecule completed
Quick answer
NNC 0172-0000-2021 for Congenital Bleeding Disorder is a Phase 1 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Congenital Bleeding Disorder
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed